Venmax Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE154G01022
NSEID:
BSEID: 531015
View on BSE

INR

28.00

1.95 (7.49%)

BSENSE

Apr 20

BSE+NSE Vol: 3.61 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zenith Health

Desh Rakshak

Ishita Drugs

Guj. Terce Labs.

Shree Ganesh Bio

Venmax Drugs

Dipna Pharmachem

Cian Healthcare

Starsource Multi

Mono Pharmacare

Saroja Pharma In

Why is Venmax Drugs & Pharmaceuticals Ltd ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Low ability to service debt as the company has a high Debt to EBITDA ratio of -0.05 times
The company has reported losses. Due to this company has reported negative ROCE

Flat results in Dec 25

Risky - Negative EBITDA

The company has recorded a negative EBITDA of Rs. -0.19 cr
Over the past year, while the stock has generated a return of 3.40%, its profits have fallen by -7%
The stock is trading risky as compared to its average historical valuations

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Venmax Drugs for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Venmax Drugs

3.4%

0.06

52.73%

Sensex

0.23%

0.02

13.34%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

81.00%

EBIT Growth (5y)

-95.00%

EBIT to Interest (avg)

-0.35

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.56

Sales to Capital Employed (avg)

0.28

Tax Ratio

3.33%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

3.73%

ROE (avg)

0.09%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.25

EV to EBIT

-20.56

EV to EBITDA

-20.56

EV to Capital Employed

10.71

EV to Sales

4.66

PEG Ratio

Dividend Yield

ROCE (Latest)

-52.08%

ROE (Latest)

19.82%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

PAT(Latest six months)

Higher at Rs 0.05 cr

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Venmax Drugs

Profit After Tax (PAT) - Latest six months

Higher at Rs 0.05 cr

than preceding 12 month period ended Dec 2025 of Rs 0.02 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)